The Epithalon Thymalin Pinealon Triad: Longevity and Immune Resilience Research
This research protocol is designed to target three core aging-control systems simultaneously: immune competence, circadian regulation, and neuroprotection. The sequencing is intentional and aligns with known biological rhythms rather than convenience.
- Thymalin → Immune system regulation and thymic signaling
- Epithalon → Telomere-associated aging pathways and circadian regulation
- Pinealon → Neuroprotection, stress resilience, and sleep–wake modulation
These compounds act on distinct but complementary regulatory axes (immune, epigenetic/circadian, neuroendocrine). They are commonly studied together in aging-focused research cycles.
Thymalin (Morning – Immune Axis)
Thymalin supports thymic signaling and T-cell differentiation, reinforcing immune surveillance and immune system calibration. Morning administration aligns with peak daytime immune readiness and endocrine–immune crosstalk, supporting resilience, reduced inflammatory drift, and improved immune balance with aging.
Epithalon (Evening – Circadian / Telomere Axis)
Epithalon acts primarily on circadian gene expression and telomerase-related signaling. Evening dosing is critical: it coincides with nocturnal repair windows, melatonin release, and genomic maintenance processes. This timing supports sleep architecture, biological rhythm stability, and long-term cellular longevity signaling.
Pinealon (Evening – Neuroprotective Axis)
Pinealon targets neuronal metabolism, oxidative stress regulation, and cognitive preservation. Evening use complements Epithalon by supporting CNS repair and neuroplastic processes that predominate during sleep. The combined evening administration supports brain aging resistance, memory integrity, and stress-buffering capacity.
These compounds act on distinct but complementary regulatory axes (immune, epigenetic/circadian, neuroendocrine). They are commonly studied together in aging-focused research cycles. Running this research protocol synchronizes immune defense, genomic maintenance, and neural protection within their natural biological windows. The result is a coordinated longevity strategy that prioritizes system timing over stimulation—supporting durability, recovery, and functional aging rather than short-term performance spikes.
General Research Protocol Structure
- Cycle Length: 10–20 consecutive days
- Frequency: 1–2 cycles per year
- Administration Route: Injection-based protocols are historically documented; oral/sublingual formats follow different kinetics and are not interchangeable.
Compound-Specific Protocols
1. Thymalin (Immune Bioregulator)
Primary Target: Thymus, T-cell differentiation, immune signaling normalization
Typical Research Dose Range:
- 5 mg daily • Subcutaneous
Timing:
- Morning administration preferred
- Rationale: Aligns with natural immune and cortisol rhythms; avoids unnecessary immune activation late in the day.
Duration:
• Days 1–20 (run concurrently with Epitalon)
Cycle frequency:
• 1–2× per year
Rationale:
Thymalin complements Epitalon by supporting immune normalization, thymic signaling, and age-related immune resilience. Running it only during the Epitalon phase avoids unnecessary immune overstimulation while reinforcing epigenetic and repair signaling.
2. Epithalon (Epitalon) (Telomere / Circadian Bioregulator)
Primary Target: Telomerase activity, gene expression related to aging, circadian signaling
Typical Research Dose Range:
• 5 mg daily (PM) Subcutaneous
Duration:
• 20 days (max supported in human research)
Cycle frequency:
• 2× per year max (advanced longevity protocols)
- Do not extend Epitalon beyond 20 days.
Telomerase activation is powerful — respect it.
- Rationale: Epithalon interacts with pineal and circadian signaling; nighttime dosing better matches endogenous melatonin and DNA repair cycles.
Notes:
- Timing does matter here more than with most peptides.
- Evening dosing is consistently favored in longevity research models.
3. Pinealon (Neuroprotective Bioregulator)
Primary Target: CNS stress resistance, sleep quality, cognitive resilience
Typical Research Dose Range:
• 500 mcg – 1 mg daily Subcutaneous
Timing:
Evening or pre-sleep administration strongly preferred
Rationale: Pinealon modulates neuroinflammatory and excitotoxic pathways and is commonly paired with sleep-phase biology.
Duration:
• Start Day 1 with Epitalon
• Continue through Day 30 total
Pinealon is small enough to cross the BBB. Injectable delivery gives faster CNS saturation but remains gentle and stabilizing.
Notes:
- Late-day dosing is intentional; daytime administration may blunt perceived benefit.
- Often synergistic with Epithalon in circadian-focused protocols.
Phase 2: Pinealon-Only Carryover
Days 21–30
- Continue Pinealon only
• Same dose: 500 mcg – 1 mg daily
Purpose:
• Stabilizes circadian rhythm
• Locks in sleep and cognition gains
• Prevents “post-Epitalon drop-off”
Total Stack Summary
| Peptide | Daily Dose | Duration | Frequency |
| Epitalon | 5 mg/day | 20 days | 2× / year |
| Thymalin | 5 mg/day | 20 days | 1–2× / year |
| Pinealon | 0.5–1 mg/day | 30 days | Every 4–6 months |
Combined Daily Timing Example
Morning:
-
- Thymalin
- Evening / Pre-Sleep:
- Epithalon
- Pinealon
This separation respects immune vs circadian/neuro timing without overcomplication.
Sequencing Considerations
- These peptides do not require strict sequencing between each other.
- They may be started simultaneously on Day 1.
- No evidence supports “priming” one with another.
Key Cautions & Design Notes
- These are regulatory peptides, not stimulants. More is not better.
- Effects are subtle, cumulative, and system-level.
- Benefits are often delayed and persist after the cycle ends.
- Stacking with aggressive stimulatory compounds can mask outcomes.
Summary
- Thymalin: Morning, immune axis
- Epithalon: Evening, circadian/telomere axis
- Pinealon: Evening, neuroprotective axis
Run together, they form a classic longevity triad used in aging and immune resilience research. This protocol is informed by decades of experimental and clinical research on peptide bioregulators developed within the Khavinson school of gerontology, demonstrating immune, circadian, neuroprotective, and epigenetic regulatory effects.
References
- Khavinson, V. Kh., et al.
Peptides regulating human gene expression.
Neuroendocrinology Letters, 2010; 31(5): 577–589. - Khavinson, V. Kh., Linkova, N. S.
Short peptides as epigenetic regulators of gene expression.
Biogerontology, 2012; 13(1): 1–13.
doi:10.1007/s10522-011-9351-2 - Anisimov, V. N., et al.
Effect of Epithalamin on biomarkers of aging, life span, and spontaneous tumor incidence in rats.
Biogerontology, 2003; 4(4): 193–202.
doi:10.1023/A:1025118213269 - Khavinson, V. Kh., Morozov, V. G.
Thymic peptides and immune regulation.
Immunology Today, 1982; 3(1): 12–15. - Morozov, V. G., Khavinson, V. Kh.
Natural peptides of thymus and pineal gland in regulation of aging.
Mechanisms of Ageing and Development, 1997; 96(1–3): 135–144.
doi:10.1016/S0047-6374(97)00023-1 - Khavinson, V. Kh., et al.
Pinealon improves cognitive functions in elderly patients with neurodegenerative disorders.
Advances in Gerontology, 2001; 7: 89–95. - Linkova, N. S., et al.
Peptide regulation of circadian rhythms and melatonin synthesis.
Bulletin of Experimental Biology and Medicine, 2016; 160(4): 488–492.
doi:10.1007/s10517-016-3249-9 - Khavinson, V. Kh., et al.
Epigenetic mechanisms of peptide bioregulators in aging and age-related diseases.
Current Aging Science, 2015; 8(1): 8–17.
doi:10.2174/1874609808666150202122400